Abstract: The present invention provides a method of identifying novel broadly crossreactive neutralizing monoclonal antibodies using sequential antigen panning of phage display libraries, antibodies obtained in accordance with such a method, as well as fusion proteins and conjugates comprising same, and related isolated or purified nucleic acid molecules, vectors, host cells, compositions, and methods of use to inhibit an infection, reduce the severity of an infection, treat an infection, and inhibit cancer.

Abstract: This invention relates to immunoglobulin molecules comprising light chain (VL) chimeric variable domains, heavy chain (VH) chimeric variable domains, e.g., scFv antibodies that are expressed at high levels within a host cell, preferably within particular cellular compartments such as, e.g., cytosol or apoplast. The VL, VH and scFv antibody molecules comprise framework scaffolds of particularly preferred framework regions. This invention also relates to nucleic acid molecules encoding the immunoglobulin molecules of this invention, vectors expressing the immunoglobulin molecules, hosts transformed with the nucleic acid molecules and vectors, and methods of using the immunoglobulin molecules. Also described are immunoglobulin libraries as well as host cells, including transgenic plants, expressing the VL, VH or scFv antibody molecules of this invention.

Abstract: The present invention features antibodies and antibody fragments that specifically bind a CD4-inducible HIV gp120 epitope that is enhanced by binding a co-receptor for HIV, such as CCR5 or CXCR4, and pharmaceutical compositions comprising the antibodies or antibody fragments. The invention also features nucleic acids encoding the antibodies or antibody fragments, pharmaceutical compositions comprising the nucleic acids encoding the antibodies or antibody fragments, vectors comprising the nucleic acids, and cells comprising the vectors. The invention further features methods of identifying antibodies or antibody fragments with broadly neutralizing activity against HIV. The invention also features methods of inhibiting HIV entry into cells and methods of inhibiting replication of HIV in mammals, using the antibodies and nucleic acids of the invention.